FDA extends indication for ADHD treatment formulation to adolescent years

Article

The US Food and Drug Administration (FDA) recently approved Adderall XR (an extended-release formulation of mixed salts of amphetamine) as a once-daily treatment for attention deficit hyperactivity disorder in adolescents 13 to 17 years old. That action bridges an "indication gap" between earlier approval of the product for patients 6 to 12 years old and for older (18 years) adolescents and adults.

The US Food and Drug Administration (FDA) recently approved Adderall XR (an extended-release formulation of mixed salts of amphetamine) as a once-daily treatment for attention deficit hyperactivity disorder in adolescents 13 to 17 years old. That action bridges an "indication gap" between earlier approval of the product for patients 6 to 12 years old and for older (18 years) adolescents and adults.

The FDA based its approval on data that the drug's manufacturer, Shire Pharmaceuticals, provided in a supplement to its new drug application, including results of a pharmacokinetic study and a placebo-controlled, fixed-dose, clinical trial of a range of doses of once-daily Adderall XR in adolescents with ADHD. In a randomized, double-blind, placebo-controlled clinical trial, the drug was more effective than placebo in treating the symptoms of ADHD symptoms in this group of patients.

Recent Videos
Perry Roy, MD
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Breaking down toddler formulas and the confusion associated with naming, labeling | Image Credit: © University of Kentucky - © University of Kentucky - stock.adobe.com.
Image credit: Kyle Dykes
J. Thomas Megerian, MD, PhD, FAAP | Author provided
Colleen Kraft, MD | Image Credit: Children's Hospital Los Angeles
Related Content
© 2024 MJH Life Sciences

All rights reserved.